RxDoctor Payments Data

Erica Gardner

Family · Greenville, SCNPI 1104356054

Payments from drug & device makers

$7,417in general payments, 2019–2025

Across 433 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$673
  • Johnson & Johnson$498
  • Gilead$430
  • Ardelyx, Inc.$425
  • Pfizer$359
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,31899%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,417 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$53,063
Medicare patients
402
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase25$47,763
LinzessLinaclotide25$20,867
Dexlansoprazole DrDexlansoprazole26$11,694
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates64$4,288
Pantoprazole Sodium261$3,478
Esomeprazole Magnesium41$3,018
Budesonide EcBudesonide16$1,676
Omeprazole78$1,037
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl69$996
Sucralfate20$809
Famotidine91$776
CholestyramineCholestyramine (With Sugar)11$755
Lactulose11$537
Lansoprazole20$462
Hydrocortisone19$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$32$47,76325 claims
AbbVieLinzess$2,307$20,86725 claims
SandozLansoprazole$53$46220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →